car-t. one year later

on september 5.2018 health canada gave a notice of compliance [NOC] for tisagenlecleucel [kymriah]. it was the first chimeric antigen receptor [car] t-cell therapy to receive regulatory approval in canada. but here we are one year later after health canada’s approval...

managing expectations

car t-cell therapy is the next big cancer treatment hitting the canadian cancer treatment landscape— with one recently approved car t-cell therapy and another on the way for use in specific patients with B-cell acute lymphoblastic leukemia [ALL] and large B-cell...

how car-t is an opportunity for canada

the arrival of car t-cell therapy is disrupting the canadian healthcare system, but it has also offered an opportunity for canada to position itself as a leader in the delivery of car-t cell therapy – circa 6 months ago. the delays in actually providing access...